0001104659-20-001084.txt : 20200103 0001104659-20-001084.hdr.sgml : 20200103 20200103190051 ACCESSION NUMBER: 0001104659-20-001084 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200103 DATE AS OF CHANGE: 20200103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cawkwell Gail CENTRAL INDEX KEY: 0001761167 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35668 FILM NUMBER: 20507594 MAIL ADDRESS: STREET 1: C/O INTERCEPT PHARMACEUTICALS, INC. STREET 2: 10 HUDSON YARDS, FLOOR 37 CITY: NEW YORK STATE: NY ZIP: 10001 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INTERCEPT PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001270073 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223868459 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 HUDSON YARDS, 37TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 646-747-1000 MAIL ADDRESS: STREET 1: 10 HUDSON YARDS, 37TH FLOOR CITY: New York STATE: NY ZIP: 10001 FORMER COMPANY: FORMER CONFORMED NAME: INTERCEPT PHARMACEUTICALS INC DATE OF NAME CHANGE: 20031113 4 1 tm201209d1_4.xml OWNERSHIP DOCUMENT X0306 4 2019-12-31 0 0001270073 INTERCEPT PHARMACEUTICALS, INC. ICPT 0001761167 Cawkwell Gail C/O INTERCEPT PHARMACEUTICALS, INC. 10 HUDSON YARDS, FLOOR 37 NEW YORK NY 10001 0 1 0 0 SVP, Med Affairs, Safety & PV Common Stock 2019-12-31 4 M 0 262 54.63 A 18984 D Common Stock 2019-12-31 4 S 0 262 125.00 D 18722 D Common Stock 2019-12-31 4 F 0 349 123.92 D 18373 D Option to Purchase Common Stock 54.63 2019-12-31 4 M 0 262 0 D 2028-02-12 Common Stock 262 20779 D This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. The award is subject to a four-year vesting period, with 25% of shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Start Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Start Date was February 12, 2018. /s/ Mark Pruzanski, as attorney-in-fact 2020-01-03